+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05821556

Phase 2 Study of Valproic Acid and Simvastatin With Gemcitabine and Nab-paclitaxel Regimens in Untreated Metastatic Pancreatic Cancer Patients

Led by National Cancer Institute, Naples · Updated on 2026-04-14

240

Participants Needed

5

Research Sites

43 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether combining valproic acid VPA and simvastatin SIM with standard chemotherapy regimens can improve treatment outcomes for patients with untreated metastatic pancreatic ductal adenocarcinoma mPDAC. This phase 2, randomized, open-label study aims to determine if this combination extends progression-free survival compared to chemotherapy alone. The study also includes correlative analyses on tumor and blood samples to find biomarkers that might predict treatment response or side effects, potentially guiding personalized therapy. Participants receive one of two chemotherapy regimens nab-paclitaxel with gemcitabine AG or nab-paclitaxel with gemcitabine, cisplatin, and capecitabine PAXG. Alongside chemotherapy, the experimental group takes a daily fixed dose of 20 mg simvastatin plus valproic acid with dose adjustments to reach target blood levels. Treatments start within three days of randomization and are given in 28-day cycles for up to six cycles or until disease progression, unacceptable toxicity, or other reasons for stopping. Patients showing clinical benefit may continue treatment beyond six cycles. After treatment, all participants enter a follow-up period. During the study, researchers monitor patients for progression-free survival over 40 months along with tumor response, survival, toxicity, and quality of life. Assessments include imaging tests to measure disease status and blood tests for safety and biomarker evaluation. Follow-up lasts up to 10 months after enrollment for primary outcome evaluation, with patients followed until death to collect further treatment data. This thorough monitoring aims to understand both effectiveness and safety of the combination treatment in real-world settings.

CONDITIONS

Brief Title

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Research Team

A

Antonio Avallone

A

Alessandra Leone

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here